Skip to main content
Premium Trial:

Request an Annual Quote

Nucleonics Wins $1.6M from NIAID for RNAi-Based Hep B Study

NEW YORK, Sept. 26 (GenomeWeb News) - Malvern, Pa.-based Nucleonics announced yesterday that it had received a four-year, $1.6 million grant from the National Institute of Allergy and Infectious Disease to develop RNAi reagents and methods against the Hepatitis B virus.


The company will collaborate with the Scripps Research Institute and the Doylestown, Pa.-based Hepatitis B Foundation on the project, which will be aimed toward the eventual development of a therapeutic for Hepatits B.


Nucleonics uses expressed interfering RNA, or eiRNA, for its gene silencing techniques.


The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.